JPRN-jRCT2080221797未知3 期
Double-blind comparative study of SYR-472
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点开始时间: 2012年5月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •The subject is an outpatient.
- •- The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
排除标准
- •- The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
- •- The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.
研究者
相似试验
已完成
3 期
Double-blind Comparative Study of SYR-472Diabetes MellitusNCT01632007Takeda245
未知
2 期
A phase II dose-ranging study of SYR-472Diabetes mellitusJPRN-jRCT2080220868Takeda Pharmaceutical Company Limited
已完成
2 期
Efficacy of SYR-472 in Subjects With Type 2 Diabetes MellitusDiabetes MellitusNCT00653185Takeda369
已完成
3 期
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT02324569Takeda240
未知
3 期
ong-term study of SYR-472Diabetes mellitusJPRN-jRCT2080221552TAKEDA PHARMACEUTICAL COMPANY LTD.622